New Zealand ends automatic Resident Visa bans for hepatitis B and C

New Zealand has removed hepatitis B and C from the medical conditions that automatically disqualify Resident Visa applicants. As of Aug. 3, Immigration New Zealand (INZ) reviews affected applicants case by case instead of issuing blanket declines, easing a long-standing barrier for people aiming to settle permanently.

What changed

Previously, applicants who tested positive for hepatitis B surface antigen or hepatitis C RNA automatically failed the acceptable standard of health requirement, unless they secured an exceptional medical waiver. INZ had treated both conditions as high-cost burdens on state health resources.

Now, assessors weigh each applicant's individual medical circumstances rather than rejecting outright. The shift mirrors how HIV has been handled since late 2021, when it also moved to case-by-case review. The state drug-funding agency Pharmac backed the change, noting that newer antiviral treatments have pushed the average cost of managing both conditions well below the relevant spending cap.

Applicants still must show that their expected health care costs won't exceed the statutory threshold of NZD $81,000 (roughly $49,000) over five years. That threshold, up from NZD $41,000 before September 2022, remains unchanged.

Who it applies to

The updated standard covers Resident Visa applications lodged on or after Aug. 3, including files under the Skilled Migrant Category, Work to Residence, and employer-assisted pathways. Applications submitted before that date are still assessed under the older, stricter rules.

Panel physicians will continue to run specific diagnostic tests during the immigration medical exam, including viral load testing, liver function tests, and antigen counts.

What it means for nomads

For short-term visitors and remote workers on standard entry visas, little changes day to day, since those routes rarely require a full medical examination. The real impact is for anyone thinking beyond a temporary stay.

If you have been managing hepatitis B or C and viewed New Zealand as off-limits for permanent residency, that door is no longer automatically closed. The practical hurdle is now demonstrating that your care fits within the NZD $81,000 five-year cost ceiling. Anyone in this position should gather recent clinical notes from their treating physician and confirm their treatment plan sits comfortably below that threshold before filing.

For globally mobile remote workers weighing where to put down longer-term roots, the move signals a more evidence-based approach to medical screening, bringing hepatitis in line with how New Zealand already handles HIV.

Originally reported by Stamped Nomad.